Cargando…
Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His
Expression of p.Arg117His cystic fibrosis (CF) transmembrane conductance regulator is influenced by a polythymidine (poly-T) tract and a thymidine–guanine (TG) repeat on intron 9, which vary in length and affect exon 10 skipping. We compared clinical characteristics and the rate of progression of lu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566269/ https://www.ncbi.nlm.nih.gov/pubmed/28845426 http://dx.doi.org/10.1183/23120541.00056-2016 |
_version_ | 1783258521696993280 |
---|---|
author | Shteinberg, Michal Downey, Damian G. Beattie, Diane McCaughan, John Reid, Alastair Stein, Nili Elborn, J. Stuart |
author_facet | Shteinberg, Michal Downey, Damian G. Beattie, Diane McCaughan, John Reid, Alastair Stein, Nili Elborn, J. Stuart |
author_sort | Shteinberg, Michal |
collection | PubMed |
description | Expression of p.Arg117His cystic fibrosis (CF) transmembrane conductance regulator is influenced by a polythymidine (poly-T) tract and a thymidine–guanine (TG) repeat on intron 9, which vary in length and affect exon 10 skipping. We compared clinical characteristics and the rate of progression of lung disease of CF patients carrying the p.Arg117His mutation with different intron 9 varying sequences (poly-T) and mutation classes in trans. Data were collected from patients in Northern Ireland, UK, including diagnostic features, sweat chloride, nutritional status, sputum microbiology, CF-related complications and lung function. Poly-T and TG repeats were determined by PCR. Forced expiratory volume in 1 s (FEV(1)) decline was determined from linear regression of FEV(1) measurements of patients over time. We identified 62 patients with p.Arg117His, 55 with a class I/II mutation in trans and six with p.Arg117His/p.Gly551Asp. 42 patients had 5T and 13 had 7T. All patients had 12 TG repeats. Patients with p.Arg117His-5T had greater lung function decline, sweat chloride concentrations, pancreatic insufficiency and prevalence of Pseudomonas aeruginosa infection compared with patients with p.Arg117His-7T. Lung function decline and disease severity in p.Arg117His is determined by the poly-T tract length and identity of the mutation in trans. Patients with p.Arg117His-5T and a second class I/II mutation have a severity similar to p.Phe508del homozygous patients, although lung function decline is delayed to an older age. There may be linkage disequilibrium between p.Arg117His and 12 TG repeats. |
format | Online Article Text |
id | pubmed-5566269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-55662692017-08-25 Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His Shteinberg, Michal Downey, Damian G. Beattie, Diane McCaughan, John Reid, Alastair Stein, Nili Elborn, J. Stuart ERJ Open Res Original Articles Expression of p.Arg117His cystic fibrosis (CF) transmembrane conductance regulator is influenced by a polythymidine (poly-T) tract and a thymidine–guanine (TG) repeat on intron 9, which vary in length and affect exon 10 skipping. We compared clinical characteristics and the rate of progression of lung disease of CF patients carrying the p.Arg117His mutation with different intron 9 varying sequences (poly-T) and mutation classes in trans. Data were collected from patients in Northern Ireland, UK, including diagnostic features, sweat chloride, nutritional status, sputum microbiology, CF-related complications and lung function. Poly-T and TG repeats were determined by PCR. Forced expiratory volume in 1 s (FEV(1)) decline was determined from linear regression of FEV(1) measurements of patients over time. We identified 62 patients with p.Arg117His, 55 with a class I/II mutation in trans and six with p.Arg117His/p.Gly551Asp. 42 patients had 5T and 13 had 7T. All patients had 12 TG repeats. Patients with p.Arg117His-5T had greater lung function decline, sweat chloride concentrations, pancreatic insufficiency and prevalence of Pseudomonas aeruginosa infection compared with patients with p.Arg117His-7T. Lung function decline and disease severity in p.Arg117His is determined by the poly-T tract length and identity of the mutation in trans. Patients with p.Arg117His-5T and a second class I/II mutation have a severity similar to p.Phe508del homozygous patients, although lung function decline is delayed to an older age. There may be linkage disequilibrium between p.Arg117His and 12 TG repeats. European Respiratory Society 2017-03-31 /pmc/articles/PMC5566269/ /pubmed/28845426 http://dx.doi.org/10.1183/23120541.00056-2016 Text en Copyright ©ERS 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Original Articles Shteinberg, Michal Downey, Damian G. Beattie, Diane McCaughan, John Reid, Alastair Stein, Nili Elborn, J. Stuart Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His |
title | Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His |
title_full | Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His |
title_fullStr | Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His |
title_full_unstemmed | Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His |
title_short | Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His |
title_sort | lung function and disease severity in cystic fibrosis patients heterozygous for p.arg117his |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566269/ https://www.ncbi.nlm.nih.gov/pubmed/28845426 http://dx.doi.org/10.1183/23120541.00056-2016 |
work_keys_str_mv | AT shteinbergmichal lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his AT downeydamiang lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his AT beattiediane lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his AT mccaughanjohn lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his AT reidalastair lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his AT steinnili lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his AT elbornjstuart lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his |